Successful use of once-daily high-dose darunavir and dolutegravir in multidrug-resistant HIV.

WHAT IS KNOWN AND OBJECTIVE?: Antiretroviral (ARV) resistance may result during periods of consistently poor adherence. We report the successful use of a novel once-daily (QD) ARV regimen in a patient with multidrug-resistant (MDR) HIV. CASE SUMMARY: Once-daily darunavir 1200 mg/ritonavir 100 mg, dolutegravir and emtricitabine/tenofovir alafenamide was initiated with directly observed therapy.

The use of unboosted darunavir in the setting of ritonavir intolerance: three case reports.

Objective: To describe three patients with human immunodeficiency virus (HIV) who were successfully managed with unboosted darunavir (uDRV).

Case Summaries: The three cases included one woman and two men aged 58, 54, and 51 years, respectively. All patients were HIV positive and unable to tolerate ritonavir-boosted protease inhibitors secondary to significant gastrointestinal intolerance.